EFFECTIVENESS OF DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER IN THE FIRST TREATMENT LINE

被引：0
|
作者：
Villa, J. C. [1 ]
Espinosa, J. [1 ]
Gomez, R. [1 ]
Sanchez, V [1 ]
Lopez, R. [1 ]
Galan, R. [1 ]
Pineda, M. D. [1 ]
Perez, M. [1 ]
机构：
[1] Ciudad Real Univ Gen Hosp, Ciudad Real, Spain
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.236
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN8
引用
收藏
页码：A816 / A817
页数：2
相关论文
共 50 条
  • [41] Docetaxel Still the Optimal First Choice for Symptomatic Metastatic Castration-Resistant Prostate Cancer
    Dreicer, Robert
    Li, Jing
    Armstrong, Andrew J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (05) : 293 - +
  • [42] Survival outcome in patients with metastatic castration-resistant prostate cancer according to first-line treatment.
    Gross-Goupil, Marine
    Thurin, Nicolas H.
    Rouyer, Magali
    Jove, Jeremy
    Haaser, Thibaud
    Rebillard, Xavier
    Soulie, Michel
    de Pouvourville, Gerard
    Pierres, Marie
    Capone, Camille
    Lamarque, Stephanie
    Bignon, Emmanuelle
    Droz-Perroteau, Cecile
    Moore, Nicholas
    Blin, Patrick
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [43] Association of body composition with survival and efficacy of first-line treatment in patients with castration-resistant prostate cancer
    Joung, Jae Young
    Pak, Sahyun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [44] Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
    Caffo, Orazio
    Ortega, Cinzia
    Nole, Franco
    Gasparro, Donatello
    Mucciarini, Claudia
    Aieta, Michele
    Zagonel, Vittorina
    Iacovelli, Roberto
    De Giorgi, Ugo
    Facchini, Gaetano
    Veccia, Antonello
    Palesandro, Erica
    Verri, Elena
    Buti, Sebastiano
    Razzini, Giorgia
    Bozza, Giovanni
    Maruzzo, Marco
    Ciccarese, Chiara
    Schepisi, Giuseppe
    Rossetti, Sabrina
    Maines, Francesca
    Kinspergher, Stefania
    Fratino, Lucia
    Ermacora, Paola
    Nicodemo, Maurizio
    Giordano, Monica
    Sartori, Donata
    Scapoli, Daniela
    Sabbatini, Roberto
    Lo Re, Giovanni
    Morelli, Franco
    D'Angelo, Alessandro
    Vittimberga, Isabella
    Lippe, Paolo
    Carrozza, Francesco
    Messina, Caterina
    Galli, Luca
    Valcamonico, Francesca
    Porta, Camillo
    Pappagallo, Giovanni
    Aglietta, Massimo
    EUROPEAN JOURNAL OF CANCER, 2021, 155 : 56 - 63
  • [45] Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel
    Buttigliero, C.
    Tucci, M.
    Vignani, F.
    Pisano, C.
    Bertaglia, V.
    Pignataro, D.
    Bironzo, P.
    Guglielmini, P. F.
    Scagliotti, G. V.
    Di Maio, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
    Onishi, Kenta
    Miyake, Makito
    Hori, Shunta
    Onishi, Sayuri
    Iida, Kota
    Morizawa, Yosuke
    Tatsumi, Yoshihiro
    Nakai, Yasushi
    Tanaka, Nobumichi
    Fujimoto, Kiyohide
    ONCOLOGY LETTERS, 2020, 19 (03) : 2306 - 2316
  • [47] Retreatment with docetaxel in metastatic castration-resistant prostate cancer (CRPC).
    Gernone, A.
    Pagliarulo, A.
    Pagliarulo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
    Wu, Kai-Jie
    Pei, Xin-Qi
    Tian, Ge
    Wu, Da-Peng
    Fan, Jin-Hai
    Jiang, Yu-Mei
    He, Da-Lin
    ASIAN JOURNAL OF ANDROLOGY, 2018, 20 (02) : 173 - 177
  • [49] Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
    Kume, Haruki
    Kawai, Taketo
    Nagata, Masayoshi
    Azuma, Takeshi
    Miyazaki, Hideyo
    Suzuki, Motofumi
    Fujimura, Tetsuya
    Nakagawa, Tohru
    Fukuhara, Hiroshi
    Homma, Yukio
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (02) : 303 - 307
  • [50] Docetaxel with or without zoledronic acid for castration-resistant prostate cancer
    Yue Pan
    Haiyong Jin
    Wei Chen
    Zhixian Yu
    Tingyu Ye
    Yuancai Zheng
    Zhiliang Weng
    Feng Wang
    International Urology and Nephrology, 2014, 46 : 2319 - 2326
12345